SCHEMBL10079207

SCHEMBL10079207

CC(=O)Oc1ccc(N)cc1C(OC(C)=O)OC(C)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 3/20 0.41
GAA P10253 1/20 0.41
RAB9A P51151 1/20 0.41
CFD P00746 2/20 0.40
CYP19A1 P11511 1/20 0.40
NR3C1 P04150 1/20 0.39
TNFSF11 O14788 1/20 0.35
ESR1 P03372 1/20 0.35
ITGB3 P05106 1/20 0.35
ITGA2B P08514 1/20 0.35
HMGB1 P09429 1/20 0.35
HPGD P15428 1/20 0.35
GGT1 P19440 1/20 0.35
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35
BLM P54132 1/20 0.35
NAPRT Q6XQN6 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10061893 0.85 ALDH1A1 (0.40) TSHRALDH1A1KDM4EGAARAB9A
SCHEMBL10351088 0.81 KDM4E (0.51) TSHRALDH1A1KDM4EGAARAB9A
SCHEMBL10438024 0.81 ALDH1A1 (0.46) TSHRALDH1A1KDM4EGAARAB9A
SCHEMBL6247630 0.78 TSHR (0.58) TSHRALDH1A1KDM4EGAARAB9A
SCHEMBL987450 0.77 ALDH1A1 (0.47) TSHRALDH1A1KDM4EGAARAB9A
SCHEMBL11327929 0.76 CFD (0.44) TSHRALDH1A1KDM4EGAARAB9A
SCHEMBL11319980 0.76 CFD (0.44) TSHRALDH1A1KDM4EGAARAB9A
SCHEMBL4520980 0.75 ACHE (0.46) TSHRALDH1A1KDM4EGAARAB9A
SCHEMBL17072170 0.75 GAA (0.49) TSHRALDH1A1KDM4EGAARAB9A
SCHEMBL10079209 0.75 RECQL (0.51) KDM4EGAARAB9APTGS2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10034851-B2 Metal-salen complex compound, local anesthetic and antineoplastic drug IHI CORPORATION (JP) 2018-07-31 US disclosed
US-10034941-B2 Iron-salen complex IHI CORPORATION (JP) 2018-07-31 US disclosed
US-10030039-B2 Anti-cancer agent and cancer cell killing method IHI CORPORATION (JP) 2018-07-24 US disclosed
EP-2557155-B1 METAL SALEN COMPLEX DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF IHI CORP (JP) 2018-06-13 EP disclosed
US-9779862-B2 Magnetic substance and magnetic substance manufacturing method IHI CORPORATION (JP) 2017-10-03 US disclosed
US-20170240581-A1 ANTI-CANCER AGENT AND CANCER CELL KILLING METHOD ISHIKAWA, YOSHIHIRO (JP) 2017-08-24 US disclosed
US-9603940-B2 Metal salen complex derivative and process for production thereof IHI CORPORATION (JP) 2017-03-28 US disclosed
US-9505732-B2 Auto magnetic metal salen complex compound IHI CORPORATION (JP) 2016-11-29 US disclosed
US-9469668-B2 Magnetic substance IHI CORPORATION (JP) 2016-10-18 US disclosed
US-20160263074-A1 METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG ISHIKAWA YOSHIHIRO (JP) 2016-09-15 US disclosed
US-20140206635-A1 METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG IHI CORPORATION (JP) 2014-07-24 US disclosed
US-20140046021-A1 SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND IHI CORPORATION (JP) 2014-02-13 US disclosed
US-20140011032-A1 METAL-SALEN COMPLEX COMPOUND AND METHOD FOR PRODUCING THE SAME IHI CORPORATION (JP) 2014-01-09 US disclosed
US-20130131367-A1 ANTI-BRAIN-TUMOR DRUG IHI CORPORATION (JP) 2013-05-23 US disclosed
US-20130090539-A1 FLUOROCHROME MATERIAL AND METHOD FOR USING THE SAME IHI CORPORATION (JP) 2013-04-11 US disclosed
EP-2557155-A1 METAL SALEN COMPLEX DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF IHI Corporation (JP) 2013-02-13 EP disclosed
US-20130029399-A1 METAL SALEN COMPLEX DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF YOSHIHIRO ISHIKAWA (JP) 2013-01-31 US disclosed
US-20120029167-A1 AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND YOSHIHIRO ISHIKAWA (JP) 2012-02-02 US disclosed
US-20090169484-A1 IRON-SALEN COMPLEX IHI CORPORATION (JP) 2009-07-02 US disclosed
US-20090169484-A1 IRON-SALEN COMPLEX IHI CORPORATION (JP) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131367-A1 ANTI-BRAIN-TUMOR DRUG SLC30A5, SLC40A1, AIFM2 TSHR 404/4885ALDH1A1 2909/4885KDM4E 1160/4885
US-20120029167-A1 AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND SDHB, SDHA, SLC40A1 TSHR 3537/4885ALDH1A1 2998/4885KDM4E 2197/4885
US-20140206635-A1 METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG NCLN, KCNN2, NCSTN TSHR 3871/4885ALDH1A1 1531/4885KDM4E 2587/4885
US-10034851-B2 Metal-salen complex compound, local anesthetic and antineoplastic drug NCLN, KCNN2, NCSTN TSHR 3871/4885ALDH1A1 1531/4885KDM4E 2587/4885
US-10034941-B2 Iron-salen complex SLC40A1, SDHB, TFRC TSHR 1446/4885ALDH1A1 904/4885KDM4E 2864/4885
US-20140046021-A1 SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND SSBP1, KCNN1, IMMT TSHR 4241/4885ALDH1A1 2799/4885KDM4E 3391/4885
US-20130029399-A1 METAL SALEN COMPLEX DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF NCLN, SPEN, SSBP1 TSHR 3782/4885ALDH1A1 2808/4885KDM4E 3433/4885
US-20130090539-A1 FLUOROCHROME MATERIAL AND METHOD FOR USING THE SAME MB, FECH, TFRC TSHR 1854/4885ALDH1A1 1453/4885KDM4E 3497/4885
US-20170240581-A1 ANTI-CANCER AGENT AND CANCER CELL KILLING METHOD BOD1L1, NUMA1, BUB1 TSHR 4746/4885ALDH1A1 3810/4885KDM4E 3993/4885
US-20090169484-A1 IRON-SALEN COMPLEX SLC40A1, SDHB, TFRC TSHR 1446/4885ALDH1A1 904/4885KDM4E 2864/4885
US-20160263074-A1 METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG NCLN, KCNN2, NCSTN TSHR 3871/4885ALDH1A1 1531/4885KDM4E 2587/4885
US-10030039-B2 Anti-cancer agent and cancer cell killing method BOD1L1, NUMA1, BUB1 TSHR 4746/4885ALDH1A1 3810/4885KDM4E 3993/4885
US-20140011032-A1 METAL-SALEN COMPLEX COMPOUND AND METHOD FOR PRODUCING THE SAME SNRNP200, MB, SDHB TSHR 568/4885ALDH1A1 3591/4885KDM4E 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.